ASCO 2018

Aktuelles in 100 Sekunden - Fazit

Aktuelles in 100 Sekunden - Die Idee

Biosimilar ABP 980

Biosimilars ASCO 2018

Zuverlässige Option für Patientinnen mit platinresistentem Ovarialkarzinom

Bedeutung von PROs

Guter Langzeitbenefit für perioperative Chemoimmuntherapie

EBC BRCA+: Neoadjuvant talazoparib for operable breast cancer patients

CDK 4/6 Update

ASCO 2018 - Mammakarzinom

MBC HR+/HER2-: Sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate)

EBC BRCA+: Prophylactic irradiation to the contralateral breast for BRCA mutation carriers

EBC HER2+: PERSEPHONE (6 vs. 12 months trastuzumab) & PERELISA De-escalated neodajuvant treatment with trastuzumab-pertuzumab-letrozole

TNBC: GeparNuevo - The addition of durvalumab to a taxane-anthracycline containing neoadjuvant chemotherapy

PI3K & AKT Pathway: SANDPIPER - Taselisib, PAKT - Capivasertib & LOTUS - Ipatasertib

ASCO 2018 - Mammakarzinom

MBC HER2+: Trastuzumab deruxtecan in subjects previously treated with T-DM1

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial

Persistence of circulating tumor cells in high risk EBC five years after adjuvant chemotherapy

EBC HR+/HER2-: TAILORx: Chemoendocrine therapy vs. endocrine therapy alone - ab dem 8. Juni 2018

MBC HR+/HER2-: MONALEESA-3, PALOMA-2, Monarch 3

Irradiation therapy: EORTC Trial 22922/10925 and Pembrolizumab plus radiotherapy in mTNBC

A.R.R.O.W.

Hematologic Malignancies - Plasma Cell Dyscrasia

OPTIMISMM

Melanom Highlights

Arthralgieschmerz, Polyneuropathie, Rash

Metastasiertes Urothelkarzinom

Blasenkarzinom - Übersicht und PD-L1 Testung

mRCC: CARMENA - Cytoreductive nephrectomy aus der Sicht eines Onkologen

Immunantwort

Immunonkologie Prostatakarzinom

Nierenzellkarzinom

mRCC: CARMENA - Cytoreductive nephrectomy aus der Sicht eines Urologen

Neue Guideline Geriatrisches Assessment

Kopf-Hals-Tumoren

CML & NSCLC

ASCO Voices

Weichgewebssarkome

Outtakes